FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson's (J&J) nipocalimab for treating individuals with moderate-to-severe Sjögren’s disease (SjD).
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson's (J&J) nipocalimab for treating individuals with moderate-to-severe Sjögren’s disease (SjD).
What's Your Reaction?
